



4/14/05

ANSWER 1 OF 6 CAPLUS. COPYRIGHT 2005 ACS on STN  
 ACCESSION NUMBER: 2001:581881 CAPLUS  
 DOCUMENT NUMBER: 135:152986  
 TITLE: Preparation of C7 carbonate substituted taxanes for  
 use as antitumor agents  
 INVENTOR(S): Holton, Robert A.  
 PATENT ASSIGNEE(S): Florida State University Research Foundation, Inc.,  
 USA  
 SOURCE: PCT Int. Appl., 83 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 9  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001057030	A1	20010809	WO 2001-US3554	20010202
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2368540	AA	20010809	CA 2001-2368540	20010202
AU 2001034793	A5	20010814	AU 2001-34793	20010202
AU 776122	B2	20040826		
BR 2001004351	A	20020102	BR 2001-4351	20010202
EP 1165552	A1	20020102	EP 2001-906952	20010202
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
US 2002052403	A1	20020502	US 2001-776426	20010202
US 6638973	B2	20031028		
US 2002065304	A1	20020530	US 2001-776137	20010202
US 6780879	B2	20040824		
TR 200102857	T1	20020621	TR 2001-200102857	20010202
JP 2003522170	T2	20030722	JP 2001-557862	20010202
EP 1285919	A1	20030226	EP 2001-118727	20010806
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
NO 2001004755	A	20011129	NO 2001-4755	20011001
BG 105966	A	20020731	BG 2001-105966	20011001
ZA 2001008051	A	20031201	ZA 2001-8051	20011001
US 2004097579	A1	20040520	US 2003-680649	20031007
US 2004138267	A1	20040715	US 2003-743581	20031222
PRIORITY APPLN. INFO.:			US 2000-179671P	P 20000202
			US 2000-179669P	P 20000202
			US 2000-179670P	P 20000202
			US 2000-179672P	P 20000202
			US 2000-179684P	P 20000202
			US 2000-179782P	P 20000202
			US 2000-179793P	P 20000202
			US 2000-179794P	P 20000202
			US 2001-776137	A1 20010202
			US 2001-776426	A3 20010202
			WO 2001-US3554	W 20010202

OTHER SOURCE(S): MARPAT 135:152986  
 GI



AB Taxanes I (R = acyloxy; R1 = carbonate; R2 = keto, hydroxy, acyloxy; R3 = hydroxy; R4 = hydrido, hydroxy; X = substituted or unsubstituted alkyl, alkenyl, alkynyl; Ph, heterocyclo; X1 = COX2, CO2X2, CONHX2; X2 = hydrocarbyl, substituted hydrocarbyl, heterocyclo; Ac = acetyl) having a carbonate substituent at C(7) were prepared and tested as antitumor agents. II was prepared and had in vitro cytotoxicity of ID50 of < 1 nm against HCT116 cells. Pharmaceutical compns. containing I are described.


IT 352427-29-3P 352698-18-1P 352698-19-2P  
 352698-20-5P 352698-21-6P 352698-22-7P  
 352698-23-8P 352698-24-9P 352698-25-0P  
 352698-26-1P 352698-28-3P 352698-29-4P  
 352698-30-7P 352698-31-8P 352698-32-9P  
 352698-33-0P 352698-34-1P 352698-35-2P  
 352698-36-3P 352698-38-5P 352698-39-6P  
 352698-41-0P 352698-42-1P 352698-43-2P  
 352698-44-3P 352698-45-4P 352698-46-5P  
 352698-47-6P 352698-48-7P 352698-49-8P  
 352698-50-1P 352698-51-2P 352698-53-4P  
 352698-54-5P 352698-55-6P 352698-56-7P  
 352698-57-8P 352698-58-9P 352698-59-0P  
 352698-60-3P 352698-61-4P 352698-62-5P  
 352698-63-6P 352698-64-7P 352698-65-8P  
 352698-66-9P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (preparation of C7 carbonate substituted taxanes for use as antitumor agents)

RN 352427-29-3 CAPLUS

CN 2-Furanpropanoic acid,  $\beta$ -[[[(1,1-dimethylpropoxy)carbonyl]amino]- $\alpha$ -hydroxy-, (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-12b-(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-6,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-4-[[[(phenylmethoxy)carbonyl]oxy]-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester, ( $\alpha$ R, $\beta$ R)- (9CI)  
 (CA INDEX NAME)


Absolute stereochemistry.



RN 352698-18-1 CAPLUS

CN 2-Thiophenepropanoic acid,  $\alpha$ -hydroxy- $\beta$ -[[[(1-methylethoxy)carbonyl]amino]-, (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-12b-(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-6,11-dihydroxy-4-[(methoxycarbonyl)oxy]-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester, ( $\alpha$ R, $\beta$ R)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 352698-19-2 CAPLUS

CN 2-Thiophenepropanoic acid,  $\alpha$ -hydroxy- $\beta$ -[[[(1-methylethoxy)carbonyl]amino]-, (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-12b-(acetyloxy)-12-(benzoyloxy)-4-[(ethoxycarbonyl)oxy]-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-6,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester, ( $\alpha$ R, $\beta$ R)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 352698-20-5 CAPLUS

CN 2-Thiophenepropanoic acid,  $\alpha$ -hydroxy- $\beta$ -[(3-methyl-1-oxo-2-butenyl) amino] -, (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS) -12b-(acetyloxy) -12-(benzoyloxy) -4-[(ethoxycarbonyl) oxy] -2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-6,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester, ( $\alpha$ R, $\beta$ R) - (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 352698-21-6 CAPLUS

CN 2-Thiophenepropanoic acid,  $\beta$ -(benzoylamino)- $\alpha$ -hydroxy-, (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS) -12b-(acetyloxy) -12-(benzoyloxy) -4-[(ethoxycarbonyl) oxy] -2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-6,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester, ( $\alpha$ R, $\beta$ R) - (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 352698-22-7 CAPLUS

CN 2-Thiophenepropanoic acid,  $\beta$ -[(2-furanylcarbonyl)amino]- $\alpha$ -hydroxy-, (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-12b-(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-6,11-dihydroxy-4-[(methoxycarbonyl)oxy]-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester, ( $\alpha$ R, $\beta$ R)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 352698-23-8 CAPLUS

CN 2-Thiophenepropanoic acid,  $\beta$ -[[[(1,1-dimethylethoxy)carbonyl]amino]- $\alpha$ -hydroxy-, (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-12b-(acetyloxy)-12-(benzoyloxy)-4-[(ethoxycarbonyl)oxy]-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-6,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester, ( $\alpha$ R, $\beta$ R)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 352698-24-9 CAPLUS

CN 2-Thiophenepropanoic acid,  $\alpha$ -hydroxy- $\beta$ -[(3-methyl-1-oxo-2-butenyl) amino] -, (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-12b-(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-6,11-dihydroxy-4-[(methoxycarbonyl)oxy]-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester, ( $\alpha$ R, $\beta$ R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 352698-25-0 CAPLUS

CN 2-Thiophenepropanoic acid,  $\beta$ -[[[(1,1-dimethylethoxy) carbonyl] amino] -  $\alpha$ -hydroxy-, (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-12b-(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-6,11-dihydroxy-4-[(methoxycarbonyl)oxy]-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester, ( $\alpha$ R, $\beta$ R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 352698-26-1 CAPLUS

CN 2-Thiophenepropanoic acid,  $\beta$ -[(2-furanylcarbonyl)amino]- $\alpha$ -hydroxy-, (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-12b-(acetyloxy)-12-(benzoyloxy)-4-[(ethoxycarbonyl)oxy]-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-6,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester, ( $\alpha$ R, $\beta$ R)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 352698-28-3 CAPLUS

CN 2-Thiophenepropanoic acid,  $\alpha$ -hydroxy- $\beta$ -[[[(2-methylpropoxy)carbonyl]amino]-, (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-12b-(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-6,11-dihydroxy-4-[(methoxycarbonyl)oxy]-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester, ( $\alpha$ R, $\beta$ R)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 352698-29-4 CAPLUS

CN 2-Thiophenepropanoic acid,  $\alpha$ -hydroxy- $\beta$ -[[(2-methylpropoxy) carbonyl] amino]-, (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-12b-(acetyloxy)-12-(benzoyloxy)-4-[(ethoxycarbonyl)oxy]-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-6,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester, ( $\alpha$ R, $\beta$ R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 352698-30-7 CAPLUS

CN 2-Thiophenepropanoic acid,  $\beta$ -(benzoylamino)- $\alpha$ -hydroxy-, (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-12b-(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-6,11-dihydroxy-4-[(methoxycarbonyl)oxy]-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester, ( $\alpha$ R, $\beta$ R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.






RN 352698-31-8 CAPLUS

CN 2-Thiophenepropanoic acid,  $\alpha$ -hydroxy- $\beta$ -[(2-thienylcarbonyl)amino]-, (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-12b-(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-6,11-dihydroxy-4-[(methoxycarbonyl)oxy]-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester, ( $\alpha$ R, $\beta$ R)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 352698-32-9 CAPLUS

CN 3-Furanpropanoic acid,  $\beta$ -[[[(1,1-dimethylethoxy)carbonyl]amino]- $\alpha$ -hydroxy-, (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-12b-(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-6,11-dihydroxy-4-[(methoxycarbonyl)oxy]-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester, ( $\alpha$ R, $\beta$ S)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 352698-33-0 CAPLUS

CN 2-Thiophenepropanoic acid,  $\alpha$ -hydroxy- $\beta$ -[(2-thienylcarbonyl)amino]-, (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-12b-(acetyloxy)-12-(benzoyloxy)-4-[(ethoxycarbonyl)oxy]-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-6,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester, ( $\alpha$ R, $\beta$ R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 352698-34-1 CAPLUS

CN 3-Thiophenepropanoic acid,  $\beta$ -[[[(1,1-dimethylethoxy)carbonyl]amino]- $\alpha$ -hydroxy-, (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-12b-(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-6,11-dihydroxy-4-[(methoxycarbonyl)oxy]-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester, ( $\alpha$ R, $\beta$ S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 352698-35-2 CAPLUS

CN 4-Hexenoic acid, 3-[[[(1,1-dimethylethoxy)carbonyl]amino]-2-hydroxy-5-methyl-, (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-12b-(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-6,11-dihydroxy-4-[(methoxycarbonyl)oxy]-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester, (2R,3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 352698-36-3 CAPLUS

CN 3-Thiophenepropanoic acid,  $\beta$ -[[[(1,1-dimethylethoxy)carbonyl]amino]- $\alpha$ -hydroxy-, (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-12b-(acetyloxy)-12-(benzoyloxy)-4-[(ethoxycarbonyl)oxy]-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-6,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester, ( $\alpha$ R, $\beta$ S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 352698-38-5 CAPLUS

CN 4-Hexenoic acid, 3-[[[(1,1-dimethylethoxy) carbonyl]amino]-2-hydroxy-5-methyl-, (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-12b-(acetyloxy)-12-(benzoyloxy)-4-[(ethoxycarbonyl)oxy]-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-6,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester, (2R,3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 352698-39-6 CAPLUS

CN 2-Furanpropanoic acid,  $\beta$ -[[[(1,1-dimethylethoxy) carbonyl]amino]- $\alpha$ -hydroxy-, (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-12b-(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-6,11-dihydroxy-4-[(methoxycarbonyl)oxy]-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester, ( $\alpha$ R, $\beta$ R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 352698-41-0 CAPLUS

CN 3-Furanpropanoic acid,  $\alpha$ -hydroxy- $\beta$ -[[ (2-methylpropoxy) carbonyl] amino] -, (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-12b-(acetyloxy)-12-(benzyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-6,11-dihydroxy-4-[(methoxycarbonyl) oxy]-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester, ( $\alpha$ R, $\beta$ S)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 352698-42-1 CAPLUS

CN Cyclopropanepropanoic acid,  $\beta$ -[[ (1,1-dimethylethoxy) carbonyl] amino] -  $\alpha$ -hydroxy-, (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-12b-(acetyloxy)-12-(benzyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-6,11-dihydroxy-4-[(methoxycarbonyl) oxy]-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester, ( $\alpha$ R, $\beta$ S)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 352698-43-2 CAPLUS

CN 3-Furanpropanoic acid,  $\alpha$ -hydroxy- $\beta$ -[[ (2-methylpropoxy) carbonyl] amino] -, (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-12b-(acetyloxy)-12-(benzoyloxy)-4-[(ethoxycarbonyl)oxy]-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-6,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester, ( $\alpha$ R, $\beta$ S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 352698-44-3 CAPLUS

CN 4-Hexenoic acid, 2-hydroxy-5-methyl-3-[[ (2-methylpropoxy) carbonyl] amino] -, (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-12b-(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-6,11-dihydroxy-4-[(methoxycarbonyl)oxy]-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester, (2R,3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 352698-45-4 CAPLUS

CN 2-Furanpropanoic acid,  $\alpha$ -hydroxy- $\beta$ -[[(2-methylpropoxy)carbonyl]amino]-, (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-12b-(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-6,11-dihydroxy-4-[(methoxycarbonyl)oxy]-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester, ( $\alpha$ R, $\beta$ R)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 352698-46-5 CAPLUS

CN 3-Thiophenepropanoic acid,  $\alpha$ -hydroxy- $\beta$ -[[(2-methylpropoxy)carbonyl]amino]-, (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-12b-(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-6,11-dihydroxy-4-[(methoxycarbonyl)oxy]-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester, ( $\alpha$ R, $\beta$ S)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 352698-47-6 CAPLUS

CN 4-Hexenoic acid, 2-hydroxy-5-methyl-3-[[[(2-methylpropoxy) carbonyl] amino] - , (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS) -12b- (acetyloxy) -12- (benzoyloxy) -4- [(ethoxycarbonyl) oxy] -2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-6,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester, (2R,3S) - (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 352698-48-7 CAPLUS

CN 2-Furanpropanoic acid,  $\alpha$ -hydroxy- $\beta$ -[[[(2-methylpropoxy) carbonyl] amino] - , (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS) -12b- (acetyloxy) -12- (benzoyloxy) -4- [(ethoxycarbonyl) oxy] -2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-6,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester, ( $\alpha$ R, $\beta$ R) - (9CI) (CA INDEX NAME)

Absolute stereochemistry.






RN 352698-49-8 CAPLUS

CN 2-Furanpropanoic acid,  $\alpha$ -hydroxy- $\beta$ -[[(2E)-1-oxo-2-butenyl]amino]-, (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-12b-(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-6,11-dihydroxy-4-[(methoxycarbonyl)oxy]-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester, ( $\alpha$ R, $\beta$ R) - (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.




RN 352698-50-1 CAPLUS

CN 2-Thiophenepropanoic acid,  $\alpha$ -hydroxy- $\beta$ -[[(2E)-1-oxo-2-butenyl]amino]-, (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-12b-(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-6,11-dihydroxy-4-[(methoxycarbonyl)oxy]-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester, ( $\alpha$ R, $\beta$ R) - (9CI) (CA INDEX NAME)

Absolute stereochemistry.


Double bond geometry as shown.



RN 352693-51-2 CAPLUS

CN 2-Furanpropanoic acid, α-hydroxy-β-[(3-methyl-1-oxo-2-butenyl) amino]-, (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-12b-(acetyloxy)-12-(benzoyloxy)-4a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-6,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-4-[[[(phenylmethoxy) carbonyl]oxy]-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester, (αR,βR)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 352698-53-4 CAPLUS

CN 2-Furanpropanoic acid, α-hydroxy-β-[(3-methyl-1-oxo-2-butenyl) amino]-, (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-12b-(acetyloxy)-12-(benzoyloxy)-4a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-6,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester, (αR,βR)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 352696-54-5 CAPLUS

CN 2-Furanpropanoic acid,  $\beta$ -[[[(1,1-dimethylethoxy) carbonyl] amino]- $\alpha$ -hydroxy-, (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-12b-(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-6,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-4-[[[(phenylmethoxy) carbonyl] oxy]-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester, ( $\alpha$ R, $\beta$ R)-(9CI)  
(CA INDEX NAME)


Absolute stereochemistry.



RN 352698-55-6 CAPLUS

CN 2-Furanpropanoic acid,  $\alpha$ -hydroxy- $\beta$ -[[[(2E)-1-oxo-2-butenyl] amino]-, (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-12b-(acetyloxy)-12-(benzoyloxy)-4-[(ethoxycarbonyl) oxy]-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-6,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester, ( $\alpha$ R, $\beta$ R)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.  
Double bond geometry as shown.



RN 352698-56-7 CAPLUS

CN 2-Thiophenepropanoic acid,  $\alpha$ -hydroxy- $\beta$ -[[ (2E)-1-oxo-2-butenyl]amino]-, (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-12b-(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-6,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-4-[[ (phenylmethoxy) carbonyl]oxy]-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester, ( $\alpha$ R, $\beta$ R)-(9CI)  
(CA INDEX NAME)


Absolute stereochemistry.  
Double bond geometry as shown.



RN 352698-57-8 CAPLUS

CN 2-Thiophenepropanoic acid,  $\alpha$ -hydroxy- $\beta$ -[[ (2E)-1-oxo-2-butenyl]amino]-, (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-12b-(acetyloxy)-12-(benzoyloxy)-4-[(ethoxycarbonyl)oxy]-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-6,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester, ( $\alpha$ R, $\beta$ R)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.  
Double bond geometry as shown.



RN 352698-58-9 CAPLUS

CN 3-Furanpropanoic acid,  $\beta$ -[[[(1,1-dimethylethoxy)carbonyl]amino]- $\alpha$ -hydroxy-, (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-12b-(acetyloxy)-12-(benzoyloxy)-4-[(ethoxycarbonyl)oxy]-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-6,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester, ( $\alpha$ R, $\beta$ S)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 352698-59-0 CAPLUS

CN 3-Furanpropanoic acid,  $\alpha$ -hydroxy- $\beta$ -[[[(2E)-1-oxo-2-butenyl]amino]-, (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-12b-(acetyloxy)-12-(benzoyloxy)-4-[(ethoxycarbonyl)oxy]-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-6,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester, ( $\alpha$ R, $\beta$ S)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.




RN 352698-60-3 CAPLUS

CN 3-Furanpropanoic acid,  $\alpha$ -hydroxy- $\beta$ -[[[(2E)-1-oxo-2-butenyl]amino]-, (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-12b-(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-6,11-dihydroxy-4-[(methoxycarbonyl)oxy]-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester, ( $\alpha$ R, $\beta$ S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


Double bond geometry as shown.



RN 352698-61-4 CAPLUS

CN 3-Thiophenepropanoic acid,  $\alpha$ -hydroxy- $\beta$ -[[[(2-methylpropoxy)carbonyl]amino]-, (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-12b-(acetyloxy)-12-(benzoyloxy)-4-[(ethoxycarbonyl)oxy]-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-6,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester, ( $\alpha$ R, $\beta$ S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 352698-62-5 CAPLUS

CN 3-Thiophenepropanoic acid,  $\alpha$ -hydroxy- $\beta$ -[[(2E)-1-oxo-2-butenyl]amino]-, (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-12b-(acetyloxy)-12-(benzoyloxy)-4-[(ethoxycarbonyl)oxy]-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-6,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester, ( $\alpha$ R, $\beta$ S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.




RN 352698-63-6 CAPLUS

CN 3-Thiophenepropanoic acid,  $\alpha$ -hydroxy- $\beta$ -[[(2E)-1-oxo-2-butenyl]amino]-, (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-12b-(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-6,11-dihydroxy-4-[(methoxycarbonyl)oxy]-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester, ( $\alpha$ R, $\beta$ S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


Double bond geometry as shown.



RN 352698-64-7 CAPLUS

CN Cyclopropanepropanoic acid,  $\alpha$ -hydroxy- $\beta$ -[[[(2-methylpropoxy) carbonyl] amino] -, (2aR, 4S, 4aS, 6R, 9S, 11S, 12S, 12aR, 12bS) -12b-(acetyloxy) -12-(benzoyloxy) -4-[(ethoxycarbonyl) oxy] -2a, 3, 4, 4a, 5, 6, 9, 10, 11, 12, 12a, 12b-dodecahydro-6, 11-dihydroxy-4a, 8, 13, 13-tetramethyl-5-oxo-7, 11-methano-1H-cyclodeca[3, 4]benz[1, 2-b]oxet-9-yl ester, ( $\alpha$ R,  $\beta$ S) - (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 352698-65-8 CAPLUS

CN Cyclopropanepropanoic acid,  $\alpha$ -hydroxy- $\beta$ -[[[(2-methylpropoxy) carbonyl] amino] -, (2aR, 4S, 4aS, 6R, 9S, 11S, 12S, 12aR, 12bS) -12b-(acetyloxy) -12-(benzoyloxy) -2a, 3, 4, 4a, 5, 6, 9, 10, 11, 12, 12a, 12b-dodecahydro-6, 11-dihydroxy-4-[(methoxycarbonyl) oxy] -4a, 8, 13, 13-tetramethyl-5-oxo-7, 11-methano-1H-cyclodeca[3, 4]benz[1, 2-b]oxet-9-yl ester, ( $\alpha$ R,  $\beta$ S) - (9CI) (CA INDEX NAME)

Absolute stereochemistry.






RN 352698-66-9 CAPLUS

CN Cyclopropanepropanoic acid,  $\beta$ -[[[(1,1-dimethylethoxy)carbonyl]amino]- $\alpha$ -hydroxy-, (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-12b-(acetyloxy)-12-(benzoyloxy)-4-[(ethoxycarbonyl)oxy]-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-6,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester, ( $\alpha$ R, $\beta$ S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT:

5

THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 2 OF 6 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2001:581864 CAPLUS

DOCUMENT NUMBER: 135:152983

TITLE: Preparation and formulation of taxanes having improved solubility for pharmaceutical use as antitumor agents

INVENTOR(S): Holton, Robert A.

PATENT ASSIGNEE(S): Florida State University Research Foundation, Inc., USA

SOURCE: PCT Int. Appl., 319 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 9

## PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001057013	A1	20010809	WO 2001-US3624	20010202
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2367661	AA	20010809	CA 2001-2367661	20010202
AU 2001034810	A5	20010814	AU 2001-34810	20010202
US 2001051639	A1	20011213	US 2001-776492	20010202
US 6649632	B2	20031118		
BR 2001004358	A	20020102	BR 2001-4358	20010202
EP 1175414	A1	20020130	EP 2001-906972	20010202
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
US 2002052403	A1	20020502	US 2001-776426	20010202
US 6638973	B2	20031028		
JP 2003521545	T2	20030715	JP 2001-556863	20010202
NZ 514073	A	20040227	NZ 2001-514073	20010202
CA 2354471	AA	20030131	CA 2001-2354471	20010731
ZA 2001096333	A	20020801	ZA 2001-6333	20010801
NO 2001004752	A	20011127	NO 2001-4752	20011001
ZA 2001008055	A	20031201	ZA 2001-8055	20011001
US 2003060636	A1	20030327	US 2002-71924	20020206
US 6750245	B2	20040615		
US 2004024051	A1	20040205	US 2003-609301	20030627
US 2004034230	A1	20040219	US 2003-618063	20030711
US 2004072872	A1	20040415	US 2003-676222	20031001
US 2004097579	A1	20040520	US 2003-680649	20031007
US 2004087547	A1	20040506	US 2003-720826	20031124
US 6361446	B2	20050301		
US 2004122055	A1	20040624	US 2003-720615	20031124
US 2004138267	A1	20040715	US 2003-743581	20031222
US 2005020635	A1	20050127	US 2004-867275	20040614
PRIORITY APPLN. INFO.:			US 2000-179669P	P 20000202
			US 2000-179670P	P 20000202
			US 2000-179671P	P 20000202
			US 2000-179672P	P 20000202
			US 2000-179674P	P 20000202
			US 2000-179684P	P 20000202
			US 2000-179782P	P 20000202
			US 2000-179793P	P 20000202
			US 2000-179794P	P 20000202
			US 2001-775852	A1 20010202
			US 2001-775912	A1 20010202
			US 2001-776137	A1 20010202
			US 2001-776274	A1 20010202
			US 2001-776393	A1 20010202
			US 2001-776426	A3 20010202
			US 2001-776492	A1 20010202
			US 2001-776494	A1 20010202
			WO 2001-US3624	W 20010202
			US 2002-71924	A1 20020206

OTHER SOURCE(S):

MARPAT 135:152983

GI

\* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT \*

AB Taxanes, such as I [R7, R10 = H, acyl, carboxy, carbamoyl, etc.; X3 = alkyl, alkenyl, alkynyl, Ph, substituted Ph, heteroaryl; X5 = H, acyl, carboxyl, carboxamide, etc.] with improved solubility, were prepared for use as antitumor agents. Thus, taxotere analog II was prepared via esterification of baccatin III derivative III (R7 = COCH<sub>2</sub>Me, R10 = SiEt<sub>3</sub>) with  $\beta$ -lactam IV followed by a deprotection step using HF. The prepared taxanes were tested for cytotoxic activity against HCT116 cells. Pharmaceutical formulations of the prepared taxanes were also presented.

IT 352427-29-3P 352698-18-1P 352698-19-2P  
 352698-20-5P 352698-21-6P 352698-22-7P  
 352698-23-8P 352698-24-9P 352698-25-0P  
 352698-26-1P 352698-28-3P 352698-29-4P  
 352698-30-7P 352698-31-8P 352698-32-9P  
 352698-33-0P 352698-34-1P 352698-35-2P  
 352698-36-3P 352698-38-5P 352698-39-6P  
 352698-41-0P 352698-42-1P 352698-43-2P  
 352698-44-3P 352698-45-4P 352698-46-5P  
 352698-47-6P 352698-48-7P 352698-49-8P  
 352698-50-1P 352698-51-2P 352698-53-4P  
 352698-54-5P 352698-55-6P 352698-56-7P  
 352698-57-8P 352698-58-9P 352698-59-0P  
 352698-60-3P 352698-61-4P 352698-62-5P  
 352698-63-6P 352698-64-7P 352698-65-8P  
 352698-66-9P


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation and formulation of taxanes having improved solubility for pharmaceutical use as antitumor agents)

RN 352427-29-3 CAPLUS

CN 2-Furanpropanoic acid,  $\beta$ -[[[(1,1-dimethylpropoxy)carbonyl]amino]- $\alpha$ -hydroxy-, (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-12b-(acetyloxy)-12-(benzyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-6,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-4-[[[(phenylmethoxy)carbonyl]oxy]-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester, ( $\alpha$ R, $\beta$ R)- (3CI)  
 (CA INDEX NAME)

Absolute stereochemistry.




RN 352698-18-1 CAPLUS

CN 2-Thiophenepropanoic acid,  $\alpha$ -hydroxy- $\beta$ -[[[(1-

methylethoxy)carbonyl]amino]-, (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-12b-(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-6,11-dihydroxy-4-[(methoxycarbonyl)oxy]-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester, ( $\alpha$ R, $\beta$ R)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 352698-19-2 CAPLUS

CN 2-Thiophenepropanoic acid,  $\alpha$ -hydroxy- $\beta$ -[[[(1-methylethoxy)carbonyl]amino]-, (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-12b-(acetyloxy)-12-(benzoyloxy)-4-[(ethoxycarbonyl)oxy]-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-6,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester, ( $\alpha$ R, $\beta$ R)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 352698-20-5 CAPLUS

CN 2-Thiophenepropanoic acid,  $\alpha$ -hydroxy- $\beta$ -[[[(3-methyl-1-oxo-2-butenyl)amino]-, (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-12b-(acetyloxy)-12-(benzoyloxy)-4-[(ethoxycarbonyl)oxy]-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-6,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester, ( $\alpha$ R, $\beta$ R)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 352698-21-6 CAPLUS

CN 2-Thiophenepropanoic acid,  $\beta$ -(benzoylamino)- $\alpha$ -hydroxy-, (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-12b-(acetyloxy)-12-(benzoyloxy)-4-[(ethoxycarbonyl)oxy]-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-6,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester, ( $\alpha$ R, $\beta$ R)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 352698-22-7 CAPLUS

CN 2-Thiophenepropanoic acid,  $\beta$ -[(2-furanylcarbonyl)amino]- $\alpha$ -hydroxy-, (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-12b-(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-6,11-dihydroxy-4-[(methoxycarbonyl)oxy]-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester, ( $\alpha$ R, $\beta$ R)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 352698-23-8 CAPLUS

CN 2-Thiophenepropanoic acid,  $\beta$ -[[(1,1-dimethylethoxy) carbonyl] amino]- $\alpha$ -hydroxy-, (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-12b-(acetyloxy)-12-(benzoyloxy)-4-[(ethoxycarbonyl) oxy]-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-6,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester, ( $\alpha$ R, $\beta$ R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 352698-24-9 CAPLUS

CN 2-Thiophenepropanoic acid,  $\alpha$ -hydroxy- $\beta$ -[(3-methyl-1-oxo-2-butenyl) amino]-, (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-12b-(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-6,11-dihydroxy-4-[(methoxycarbonyl) oxy]-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester, ( $\alpha$ R, $\beta$ R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 352698-25-0 CAPLUS

CN 2-Thiophenepropanoic acid,  $\beta$ -[[[(1,1-dimethylethoxy)carbonyl]amino]- $\alpha$ -hydroxy-, (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-12b-(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-6,11-dihydroxy-4-[(methoxycarbonyl)oxy]-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester, ( $\alpha$ R, $\beta$ R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 352698-26-1 CAPLUS

CN 2-Thiophenepropanoic acid,  $\beta$ -[(2-furanylcarbonyl)amino]- $\alpha$ -hydroxy-, (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-12b-(acetyloxy)-12-(benzoyloxy)-4-[(ethoxycarbonyl)oxy]-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-6,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester, ( $\alpha$ R, $\beta$ R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 352698-28-3 CAPLUS

CN 2-Thiophenepropanoic acid,  $\alpha$ -hydroxy- $\beta$ -[[[(2-methylpropoxy) carbonyl] amino] -, (2aR, 4S, 4aS, 6R, 9S, 11S, 12S, 12aR, 12bS) -12b-(acetyloxy) -12-(benzoyloxy) -2a, 3, 4, 4a, 5, 6, 9, 10, 11, 12, 12a, 12b-dodecahydro-6, 11-dihydroxy-4-[(methoxycarbonyl) oxy] -4a, 8, 13, 13-tetramethyl-5-oxo-7, 11-methano-1H-cyclodeca[3, 4]benz[1, 2-b]oxet-9-yl ester, ( $\alpha$ R,  $\beta$ R) - (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 352698-29-4 CAPLUS

CN 2-Thiophenepropanoic acid,  $\alpha$ -hydroxy- $\beta$ -[[[(2-methylpropoxy) carbonyl] amino] -, (2aR, 4S, 4aS, 6R, 9S, 11S, 12S, 12aR, 12bS) -12b-(acetyloxy) -12-(benzoyloxy) -4-[(ethoxycarbonyl) oxy] -2a, 3, 4, 4a, 5, 6, 9, 10, 11, 12, 12a, 12b-dodecahydro-6, 11-dihydroxy-4a, 8, 13, 13-tetramethyl-5-oxo-7, 11-methano-1H-cyclodeca[3, 4]benz[1, 2-b]oxet-9-yl ester, ( $\alpha$ R,  $\beta$ R) - (9CI) (CA INDEX NAME)

Absolute stereochemistry.






RN 352698-30-7 CAPLUS

CN 2-Thiophenepropanoic acid,  $\beta$ -(benzoylamino)- $\alpha$ -hydroxy-, (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-12b-(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-6,11-dihydroxy-4-[(methoxycarbonyl)oxy]-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester, ( $\alpha$ R, $\beta$ R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 352698-31-8 CAPLUS

CN 2-Thiophenepropanoic acid,  $\alpha$ -hydroxy- $\beta$ -[(2-thienylcarbonyl)amino]-, (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-12b-(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-6,11-dihydroxy-4-[(methoxycarbonyl)oxy]-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester, ( $\alpha$ R, $\beta$ R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 352698-32-9 CAPLUS

CN 3-Furanpropanoic acid,  $\beta$ -[[(1,1-dimethylethoxy) carbonyl] amino]- $\alpha$ -hydroxy-, (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-12b-(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-6,11-dihydroxy-4-[(methoxycarbonyl)oxy]-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester, ( $\alpha$ R, $\beta$ S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 352698-33-0 CAPLUS

CN 2-Thiophenepropanoic acid,  $\alpha$ -hydroxy- $\beta$ -[(2-thienylcarbonyl) amino]-, (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-12b-(acetyloxy)-12-(benzoyloxy)-4-[(ethoxycarbonyl)oxy]-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-6,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester, ( $\alpha$ R, $\beta$ R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 352698-34-1 CAPLUS

CN 3-Thiophenepropanoic acid,  $\beta$ -[[[(1,1-dimethylethoxy) carbonyl] amino]- $\alpha$ -hydroxy-, (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-12b-(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-6,11-dihydroxy-4-[(methoxycarbonyl)oxy]-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester, ( $\alpha$ R, $\beta$ S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 352698-35-2 CAPLUS

CN 4-Hexenoic acid, 3-[[[(1,1-dimethylethoxy) carbonyl] amino]-2-hydroxy-5-methyl-, (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-12b-(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-6,11-dihydroxy-4-[(methoxycarbonyl)oxy]-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester, (2R,3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 352698-36-3 CAPLUS

CN 3-Thiophenepropanoic acid,  $\beta$ -[[[(1,1-dimethylethoxy)carbonyl]amino]- $\alpha$ -hydroxy-, (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-12b-(acetyloxy)-12-(benzoyloxy)-4-[(ethoxycarbonyl)oxy]-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-6,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester, ( $\alpha$ R, $\beta$ S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 352698-38-5 CAPLUS

CN 4-Hexenoic acid, 3-[[[(1,1-dimethylethoxy)carbonyl]amino]-2-hydroxy-5-methyl-, (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-12b-(acetyloxy)-12-(benzoyloxy)-4-[(ethoxycarbonyl)oxy]-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-6,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester, (2R,3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 352698-39-6 CAPLUS

CN 2-Furanpropanoic acid,  $\beta$ -[[[(1,1-dimethylethoxy) carbonyl] amino] -  
 $\alpha$ -hydroxy-, (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS) -12b- (acetyloxy) -12-  
 (benzoyloxy) -2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-6,11-dihydroxy-4-  
 [(methoxycarbonyl) oxy] -4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-  
 cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester, ( $\alpha$ R, $\beta$ R) - (9CI) (CA  
 INDEX NAME)


Absolute stereochemistry.



RN 352698-41-0 CAPLUS

CN 3-Furanpropanoic acid,  $\alpha$ -hydroxy- $\beta$ -[[[(2-  
 methylpropoxy) carbonyl] amino] -, (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS) -12b-  
 (acetyloxy) -12- (benzoyloxy) -2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-  
 6,11-dihydroxy-4- [(methoxycarbonyl) oxy] -4a,8,13,13-tetramethyl-5-oxo-7,11-  
 methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester, ( $\alpha$ R, $\beta$ S) -  
 (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 352698-42-1 CAPLUS

CN Cyclopropanepropanoic acid,  $\beta$ -[[[(1,1-dimethylethoxy) carbonyl] amino] -  
 $\alpha$ -hydroxy-, (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-12b-(acetyloxy)-12-  
 (benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-6,11-dihydroxy-4-  
 [(methoxycarbonyl) oxy]-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-  
 cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester, ( $\alpha$ R, $\beta$ S)- (9CI) (CA  
 INDEX NAME)


Absolute stereochemistry.



RN 352698-43-2 CAPLUS

CN 3-Furanpropanoic acid,  $\alpha$ -hydroxy- $\beta$ -[[[(2-  
 methylpropoxy) carbonyl] amino] -, (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-12b-  
 (acetyloxy)-12-(benzoyloxy)-4-[(ethoxycarbonyl) oxy]-  
 2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-6,11-dihydroxy-4a,8,13,13-  
 tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl  
 ester, ( $\alpha$ R, $\beta$ S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 352698-44-3 CAPLUS

CN 4-Hexenoic acid, 2-hydroxy-5-methyl-3-[[[(2-methylpropoxy) carbonyl] amino] -, (2aR, 4S, 4aS, 6R, 9S, 11S, 12S, 12aR, 12bS) -12b- (acetyloxy) -12- (benzoyloxy) -2a, 3, 4, 4a, 5, 6, 9, 10, 11, 12, 12a, 12b-dodecahydro-6, 11-dihydroxy-4-[(methoxycarbonyl) oxy]-4a, 8, 13, 13-tetramethyl-5-oxo-7, 11-methano-1H-cyclodeca[3, 4]benz[1, 2-b]oxet-9-yl ester, (2R, 3S) - (9CI) (CA INDEX NAME)


Absolute Stereochemistry.



RN 352698-45-4 CAPLUS

CN 2-Furanpropanoic acid,  $\alpha$ -hydroxy- $\beta$ -[[[(2-methylpropoxy) carbonyl] amino] -, (2aR, 4S, 4aS, 6R, 9S, 11S, 12S, 12aR, 12bS) -12b- (acetyloxy) -12- (benzoyloxy) -2a, 3, 4, 4a, 5, 6, 9, 10, 11, 12, 12a, 12b-dodecahydro-6, 11-dihydroxy-4-[(methoxycarbonyl) oxy]-4a, 8, 13, 13-tetramethyl-5-oxo-7, 11-methano-1H-cyclodeca[3, 4]benz[1, 2-b]oxet-9-yl ester, ( $\alpha$ R,  $\beta$ R) - (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 352698-46-5 CAPLUS

CN 3-Thiophenepropanoic acid,  $\alpha$ -hydroxy- $\beta$ -[[2-methylpropoxy]carbonyl]amino]-, (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-12b-(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-6,11-dihydroxy-4-[(methoxycarbonyl)oxy]-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester, ( $\alpha$ R, $\beta$ S)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 352696-47-6 CAPLUS

CN 4-Hexenoic acid, 2-hydroxy-5-methyl-3-[[2-methylpropoxy]carbonyl]amino]-, (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-12b-(acetyloxy)-12-(benzoyloxy)-4-[(ethoxycarbonyl)oxy]-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-6,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester, (2R,3S)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.






RN 352698-48-7 CAPLUS

CN 2-Furanpropanoic acid,  $\alpha$ -hydroxy- $\beta$ -[[[(2-methylpropoxy) carbonyl] amino]-, (2aR, 4S, 4aS, 6R, 9S, 11S, 12S, 12aR, 12bS)-12b-(acetyloxy)-12-(benzoyloxy)-4-[(ethoxycarbonyl)oxy]-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-6,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester, ( $\alpha$ R, $\beta$ R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 352698-49-8 CAPLUS

CN 2-Furanpropanoic acid,  $\alpha$ -hydroxy- $\beta$ -[[[(2E)-1-oxo-2-butenyl] amino]-, (2aR, 4S, 4aS, 6R, 9S, 11S, 12S, 12aR, 12bS)-12b-(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-6,11-dihydroxy-4-[(methoxycarbonyl)oxy]-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester, ( $\alpha$ R, $\beta$ R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.




RN 352698-50-1 CAPLUS

CN 2-Thiophenepropanoic acid,  $\alpha$ -hydroxy- $\beta$ -[[ (2E)-1-oxo-2-butenyl] amino] -, (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-12b-(acetyloxy)-12-(benzyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-6,11-dihydroxy-4-[(methoxycarbonyl)oxy]-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester, ( $\alpha$ R, $\beta$ R) - (9CI) (CA INDEX NAME)

Absolute stereochemistry.


Double bond geometry as shown.



RN 352698-51-2 CAPLUS

CN 2-Furanpropanoic acid,  $\alpha$ -hydroxy- $\beta$ -[(3-methyl-1-oxo-2-butenyl) amino] -, (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-12b-(acetyloxy)-12-(benzyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-6,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-4-[[ (phenylmethoxy) carbonyl]oxy]-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester, ( $\alpha$ R, $\beta$ R) - (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 352698-53-4 CAPLUS

CN 2-Furanpropanoic acid,  $\alpha$ -hydroxy- $\beta$ -[(3-methyl-1-oxo-2-butenyl) amino]-, (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-12b-(acetyloxy)-12-(benzoyloxy)-4-[(ethoxycarbonyl)oxy]-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-6,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester, ( $\alpha$ R, $\beta$ R)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 352698-54-5 CAPLUS

CN 2-Furanpropanoic acid,  $\beta$ -[[(1,1-dimethylethoxy) carbonyl] amino]- $\alpha$ -hydroxy-, (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-12b-(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-6,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-4-[[phenylmethoxy] carbonyl]oxy]-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester, ( $\alpha$ R, $\beta$ R)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 352698-55-6 CAPLUS

CN 2-Furanpropanoic acid,  $\alpha$ -hydroxy- $\beta$ -[[(2E)-1-oxo-2-butenyl]amino]-, (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-12b-(acetyloxy)-12-(benzoyloxy)-4-[(ethoxycarbonyl)oxy]-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-6,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester, ( $\alpha$ R, $\beta$ R) - (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.




RN 352698-56-7 CAPLUS

CN 2-Thiophenepropanoic acid,  $\alpha$ -hydroxy- $\beta$ -[[(2E)-1-oxo-2-butenyl]amino]-, (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-12b-(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-6,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-4-[[[(phenylmethoxy)carbonyl]oxy]-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester, ( $\alpha$ R, $\beta$ R) - (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.




RN 352698-57-8 CAPLUS

CN 2-Thiophenepropanoic acid, α-hydroxy-β-[[[(2E)-1-oxo-2-butenyl]amino]-, (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-12b-(acetyloxy)-12-(benzoyloxy)-4-[(ethoxycarbonyl)oxy]-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-6,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester, (αR,βR)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.


Double bond geometry as shown.



RN 352698-58-9 CAPLUS

CN 3-Furanpropanoic acid, β-[[[(1,1-dimethylethoxy)carbonyl]amino]-α-hydroxy-, (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-12b-(acetyloxy)-12-(benzoyloxy)-4-[(ethoxycarbonyl)oxy]-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-6,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester, (αR,βS)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



The chemical structure shows a complex molecule, likely a steroid derivative, featuring a pentacyclic core. The core consists of a six-membered ring fused to two five-membered rings, which are further fused to a six-membered ring and a five-membered ring. Substituents include a phenyl group (Ph), an acetoxy group (AcO), a methyl group (Me), a hydroxyl group (OH), and a complex side chain. The side chain includes a cyclopentenyl ring, a carboxylate group (COOEt), and a carboxamide group (CONHMe). Stereochemistry is indicated with wedges and dashes.

RN	352698-60-3	CAPLUS
CN	3-Furanpropanoic acid, $\alpha$ -hydroxy- $\beta$ -[[(2E)-1-oxo-2- butenyl]amino]-, (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-12b-(acetyloxy)-12- (benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-6,11-dihydroxy-4- [(methoxycarbonyl)oxy]-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H- cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester, ( $\alpha$ R, $\beta$ S)- (9CI) (CA INDEX NAME)	


Absolute stereochemistry.  
Double bond geometry as shown.



RN 352698-61-4 CAPLUS

CN 3-Thiophenepropanoic acid,  $\alpha$ -hydroxy- $\beta$ -[[ (2-methylpropoxy) carbonyl] amino] -, (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-12b-(acetyloxy)-12-(benzoyloxy)-4-[(ethoxycarbonyl) oxy]-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-6,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester, ( $\alpha$ R, $\beta$ S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 352698-62-5 CAPLUS

CN 3-Thiophenepropanoic acid,  $\alpha$ -hydroxy- $\beta$ -[[ (2E)-1-oxo-2-butenyl] amino] -, (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-12b-(acetyloxy)-12-(benzoyloxy)-4-[(ethoxycarbonyl) oxy]-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-6,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester, ( $\alpha$ R, $\beta$ S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.




RN 352698-63-6 CAPLUS

CN 3-Thiophenepropanoic acid,  $\alpha$ -hydroxy- $\beta$ -[[[(2E)-1-oxo-2-butenyl]amino]-, (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-12b-(acetyloxy)-12-(benzyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-6,11-dihydroxy-4-[(methoxycarbonyl)oxy]-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester, ( $\alpha$ R, $\beta$ S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.




RN 352698-64-7 CAPLUS

CN Cyclopropanepropanoic acid,  $\alpha$ -hydroxy- $\beta$ -[[[(2-methylpropoxy)carbonyl]amino]-, (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-12b-(acetyloxy)-12-(benzyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-6,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester, ( $\alpha$ R, $\beta$ S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.






RN 352698-65-8 CAPLUS

CN Cyclopropanepropanoic acid,  $\alpha$ -hydroxy- $\beta$ -[[[2-methylpropoxy)carbonyl]amino]-, (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-12b-(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-6,11-dihydroxy-4-[(methoxycarbonyl)oxy]-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester, ( $\alpha$ R, $\beta$ S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 352698-66-9 CAPLUS

CN Cyclopropanepropanoic acid,  $\beta$ -[[[(1,1-dimethylethoxy)carbonyl]amino]- $\alpha$ -hydroxy-, (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-12b-(acetyloxy)-12-(benzoyloxy)-4-[(ethoxycarbonyl)oxy]-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-6,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester, ( $\alpha$ R, $\beta$ S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.





REFERENCE COUNT: 22 THERE ARE 22 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 3 OF 6 CAPLUS COPYRIGHT 2005 ACS on STN  
 ACCESSION NUMBER: 2001:581700 CAPLUS  
 DOCUMENT NUMBER: 135:152982  
 TITLE: Preparation of C10 heterosubstituted acetate taxanes as antitumor agents  
 INVENTOR(S): Holton, Robert A.  
 PATENT ASSIGNEE(S): Florida State University Research Foundation, Inc., USA  
 SOURCE: PCT Int. Appl., 56 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 9  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001056564	A1	20010809	WO 2001-US3553	20010202
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2368502	AA	20010809	CA 2001-2368502	20010202
AU 2001034792	A5	20010814	AU 2001-34792	20010202
AU 776767	B2	20040923		
BR 2001004350	A	20020102	BR 2001-4350	20010202
EP 1165068	A1	20020102	EP 2001-906951	20010202
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
US 2002052403	A1	20020502	US 2001-776426	20010202
US 6638973	B2	20031028		
US 2002068755	A1	20020606	US 2001-775912	20010202
US 6664275	B2	20031216		
JP 2003521514	T2	20030715	JP 2001-556255	20010202
NZ 514406	A	20050128	NZ 2001-514406	20010202
ZA 2001006334	A	20020801	ZA 2001-6334	20010801
NO 2001004756	A	20011129	NO 2001-4756	20011001

ZA 2001008052	A	20031201	ZA 2001-8052	20011001
US 2004024051	A1	20040205	US 2003-609301	20030627
US 2004097579	A1	20040520	US 2003-680649	20031007
PRIORITY APPLN. INFO.:			US 2000-179669P	P 20000202
			US 2000-179670P	P 20000202
			US 2000-179671P	P 20000202
			US 2000-179672P	P 20000202
			US 2000-179684P	P 20000202
			US 2000-179782P	P 20000202
			US 2000-179793P	P 20000202
			US 2000-179794P	P 20000202
			US 2001-775912	A1 20010202
			US 2001-776426	A3 20010202
			WO 2001-US3553	W 20010202

OTHER SOURCE(S): MARPAT 135:152982  
CI.



AB Taxanes of formula I [R1 = H, OH; R2 = acyloxy; R3 = keto, OH, acyloxy; R4 = heterosubstituted acetate; X1 = alkyl, alkenyl, Ph, heterocyclyl; X2 = acyl, CO2alkyl, CO2heterocyclyl, etc.], having a heterosubstituted acetate substituent at C(10), are prepared as antitumor agents. Thus, II was prepared and had in vitro cytotoxicity of ID50 < 1 nm against HCT116 cells.

IT 352427-29-3P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of C10 heterosubstituted acetate taxanes as antitumor agents)

RN 352427-29-3 CAPLUS

CN 2-Furanpropanoic acid,  $\beta$ -[[[(1,1-dimethylpropoxy)carbonyl]amino]- $\alpha$ -hydroxy-, (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-12b-(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-6,11-dihydroxy-2a,8,13,13-tetramethyl-5-oxo-4-[[[(phenylmethoxy)carbonyl]oxy]-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester, ( $\alpha$ R, $\beta$ R) - (9CI)  
(CA INDEX NAME)

Absolute stereochemistry.





REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 4 OF 6 CAPLUS COPYRIGHT 2005 ACS on STN  
 ACCESSION NUMBER: 1999:656007 CAPLUS  
 DOCUMENT NUMBER: 131:272040  
 TITLE: Preparation of  $\Delta 6,7$ -taxols and oxazolidine protected intermediates as antineoplastic agents  
 INVENTOR(S): Kelly, Robert C.; Skulnick, Harvey I.  
 PATENT ASSIGNEE(S): Pharmacia and Upjohn Co., USA  
 SOURCE: U.S., 63 pp., Cont.-in-part of Appl. No. PCT/US93/11827.  
 CODEN: USXXAM

DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 3  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5965739	A	19991012	US 1995-557034	19951207
WO 9413655	A1	19940623	WO 1993-US11827	19931213
W: AT, AU, BB, BG, BR, BY, CA, CH, CZ, DE, DK, ES, FI, GB, HU, JP, KP, KR, KZ, LK, LU, LV, MG, MN, MW, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SK, UA, US, US, US, US, UZ, VN				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
WO 9429288	A1	19941222	WO 1994-US6035	19940603
W: AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, ES, FI, JP, KP, KR, NL, NO, RU, US				
RW: AT, BE, CH, DE, DK, GB, LU, MC, NL, PT, SE, CG, CM, ML, MR, NE, SN				
ZA 9404034	A	19951208	ZA 1994-4034	19940608
PRIORITY APPLN. INFO.:				
			US 1993-76337	B2 19930611
			US 1993-122974	B2 19930917
			WO 1993-US11827	A2 19931213
			WO 1994-US6035	W 19940603
			US 1992-990579	A 19921215
			US 1993-13826	A 19930202

OTHER SOURCE(S): MARPAT 131:272040  
 GI



AB Oxazolidine protected taxol analogs of formula I [R1 = Me, Ph, alkyl, alkoxy, halo, furyl, naphthyl, etc.; R2 = CHO, C(=O)Ph, acyl, CONHPh, etc.; R3 = alkoxy-substituted phenyl; R4 = H, Ac; R5 = acyl, alkoxycarbonyl, etc.], which are useful intermediates to make various taxol analogs, are prepared. Also, 7-deoxy- $\Delta$ 6,7-taxols and 7 $\beta$ ,8 $\beta$ -methanotaxols are prepared. Thus, II was prepared from 7-triethylsilylbaccatin III and (4S,5R)-N-benzoyl-2-(2,4-dimethoxyphenyl)-4-phenyl-5-oxazolidinecarboxylic acid potassium salt (preparation given). The biol. activity of 7-deoxy- $\Delta$ 6,7-taxols against L1210 leukemia is tested. Pharmaceutical compns. containing 7-deoxy- $\Delta$ 6,7-taxols are described.


IT 158810-72-1P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(preparation of  $\Delta$ 6,7-taxols and oxazolidine protected intermediates as antineoplastic agents)

PN 158810-72-1 CAPLUS

CN Benzenepropanoic acid,  $\beta$ -[[(1,1-dimethylethoxy)carbonyl]amino]- $\alpha$ -hydroxy-, (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-12b-(acetyloxy)-12-(benzoyloxy)-4-[[[(2,2-dichloroethoxy)carbonyl]oxy]-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-6,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester, ( $\alpha$ R, $\beta$ S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



REFERENCE COUNT: 71 THERE ARE 71 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 5 OF 6 CAPLUS COPYRIGHT 2005 ACS on STN  
 ACCESSION NUMBER: 1996:590913 CAPLUS  
 DOCUMENT NUMBER: 125:301270  
 TITLE: Preparation of antineoplastic  $\Delta 6,7$ -taxols  
 INVENTOR(S): Kelly, Robert C.; Johnson, Roy A.; Skulnick, Harvey I.; Nidy, Eldon G.  
 PATENT ASSIGNEE(S): Upjohn Co., USA  
 SOURCE: U.S., 66 pp., Cont.-in-part of U.S. Ser. No. 122, 974, abandoned.  
 CODEN: USXXAM  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 3  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5556878	A	19960917	US 1994-258019	19940610
PT 703909	T	20001031	PT 1994-920688	19940603
ZA 9404034	A	19951208	ZA 1994-4034	19940608
PRIORITY APPLN. INFO.:			US 1993-76337	B2 19930611
			US 1993-122974	B2 19930917
OTHER SOURCE(S):	MARPAT 125:301270			
GI				



AB 7-Deoxy- $\Delta 6,7$ -taxols I [R1 = (un)substituted Ph, Me; R2 = acylamino;

R3 = acyloxy, acylamino; R4 = H, Ac; R5 = H, (un)substituted Bz] were prepared for use as anticancer agents. N-debenzoyl-N-tert-butoxycarbonyl-7-deoxy- $\Delta$ 6,7-taxol (II) was prepared from N-debenzoyl-N-tert-butoxycarbonyl-2'-trichloroethoxycarbonyltaxol by treatment with DAST. II had an IC50 against L1210 leukemia of 0.0016  $\mu$ g/mL.


IT 158810-72-1P

RL: SPN (Synthetic preparation); PREP (Preparation)  
(preparation of antineoplastic  $\Delta$ 6,7 -taxols)

RN 158810-72-1 CAPLUS

CN Benzenepropanoic acid,  $\beta$ -[[(1,1-dimethylethoxy)carbonyl]amino]- $\alpha$ -hydroxy-, (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-12b-(acetyloxy)-12-(benzoyloxy)-4-[[[(2,2-dichloroethoxy)carbonyl]oxy]-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-6,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester, ( $\alpha$ R, $\beta$ S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L3 ANSWER 5 OF 6 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1994:680920 CAPLUS

DOCUMENT NUMBER: 121:280920

TITLE: Preparation of 7-halo- and 7 $\beta$ ,8 $\beta$ -methanotaxols, their antineoplastic use and pharmaceutical compositions containing them

INVENTOR(S): Hester, Jackson B., Jr.; Johnson, Roy A.; Kelly, Robert C.; Midy, Eldon G.; Skulnick, Harvey I.

PATENT ASSIGNEE(S): Upjohn Co., USA

SOURCE: PCT Int. Appl., 127 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 3

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9413655	A1	19940623	WO 1993-US11827	19931213
W: AT, AU, BB, BG, BR, BY, CA, CH, CZ, DE, DK, ES, FI, GB, HU, JP, KP, KR, KZ, LK, LU, LV, MG, MN, MW, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SK, UA, US, US, US, US, UZ, VN				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
ZA 9309247	A	19950609	ZA 1993-9247	19931209
IL 107950	A1	20010430	IL 1993-107950	19931209

CA 2149021	AA	19940623	CA 1993-2149021	19931213
AU 9457411	A1	19940704	AU 1994-57411	19931213
AU 687027	B2	19980219		
EP 674630	A1	19951004	EP 1994-903483	19931213
EP 674630	B1	20021023		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
JP 08506568	T2	19960716	JP 1994-514312	19931213
JP 3441458	B2	20030902		
HU 74447	A2	19961230	HU 1995-1733	19931213
RU 2125996	C1	19990210	RU 1995-114377	19931213
SK 281897	B6	20010911	SK 1995-788	19931213
AT 226576	E	20021115	AT 1994-903483	19931213
CZ 291177	B6	20030115	CZ 1995-1437	19931213
PL 185042	B1	20030228	PL 1993-309392	19931213
PT 674630	T	20030331	PT 1994-903483	19931213
ES 2187519	T3	20030616	ES 1994-903483	19931213
CN 1095377	A	19941123	CN 1993-121129	19931215
CN 1062561	B	20010228		
TW 389758	B	20000511	TW 1993-82110645	19931215
CA 2161328	AA	19941222	CA 1994-2161328	19940603
WO 9429288	A1	19941222	WO 1994-US6035	19940603
W: AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, ES, FI, JP, KP, KR, NL, NO, RU, US				
RW: AT, BE, CH, DE, DK, GB, LU, MC, NL, PT, SE, CG, CM, ML, MR, NE, SN				
AU 9471388	A1	19950103	AU 1994-71388	19940603
EP 703909	A1	19960403	EP 1994-920688	19940603
EP 703909	B1	20000426		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
JP 09511212	T2	19971111	JP 1994-501878	19940603
NZ 330671	A	20000128	NZ 1994-330671	19940603
EP 982301	A2	20000301	EP 1999-118033	19940603
EP 982301	A3	20001108		
EP 982301	B1	20030910		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI				
EP 982302	A2	20000301	EP 1999-118034	19940603
EP 982302	A3	20000719		
EP 982302	B1	20040414		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI				
AT 192147	E	20000515	AT 1994-920688	19940603
ES 2145829	T3	20000716	ES 1994-920688	19940603
AT 249448	E	20030915	AT 1999-118033	19940603
PT 982301	T	20040227	PT 1999-118033	19940603
AT 264316	E	20040415	AT 1999-118034	19940603
ES 2205663	T3	20040501	ES 1999-118033	19940603
PT 982302	T	20040730	PT 1999-118034	19940603
ES 2219968	T3	20041201	ES 1999-118034	19940603
ZA 9404034	A	19951208	ZA 1994-4034	19940608
TW 401407	B	20000811	TW 1994-83105245	19940609
IL 109957	A1	20010111	IL 1994-109957	19940609
FI 9502920	A	19950614	FI 1995-2920	19950614
FI 111633	B1	20030829		
NO 9502351	A	19950814	NO 1995-2351	19950614
US 5965739	A	19991012	US 1995-557034	19951207
AU 9889433	A1	19981210	AU 1998-89433	19981021
AU 722920	B2	20000817		
CN 1261072	A	20000726	CN 1999-124350	19991125
GR 3033836	T3	20001031	GR 2000-401537	20000630
LV 12692	B	20010920	LV 2001-64	20010426

PRIORITY APPLN. INFO.:

US 1992-990579	A	19921215
US 1993-13826	A	19930202
US 1993-76337	A	19930611
US 1993-122974	A	19930917




WO 1993-US11827  
 AU 1994-71388  
 EP 1994-920688  
 WO 1994-US6035

W 19931213  
 A3 19940603  
 A3 19940603  
 W 19940603

OTHER SOURCE(S):  
 GI

MARPAT 121:280920



I

AB Title compds. I (R1 = Me, (substituted) Ph, 2-furyl, 2-thienyl, 1- or 2-naphthyl, 3,4(OCH2O)C6H3; R2 = H, HCONH, C1-10 alkylCONH, (substituted) phenyl-CONH, HO, phthalimido, etc.; R3 = H, PhCONH, Me3CO2CNH; with the proviso that R2 and R3 ≠ H; R4 = H, HO, AcO, Cl3CCH2O2CO, PhCONH, etc.; R5 = H, HO, with the overall proviso that when R5 = HO, R4 is H and with the further proviso that when R5 = H, R4 is other than H; R6 = HH when R7 = α-R71β-R72 where one of R71 and R72 is X, where X = halo; R8 = Me; or R6 = HH when R7 is α-Hβ-R74 where R74R8 = cyclopropyl; R10 = H, Ac) and a salt thereof, are prepared. I are useful for the same cancers for which taxol has been shown active. N-debenzoyl-N-(tert-butyloxycarbonyl)-2'-trioct-taxol (preparation given) was reacted with dimethylaminosulfur trifluoride to give N-debenzoyl-N-(tert-butyloxycarbonyl)-2'-[[[2,2,2-trichloroethyl]oxy]carbonyl]-7-deoxy-1-fluorotaxol which was treated with Zn to give N-debenzoyl-N-(tert-butyloxycarbonyl)-7-deoxy-7-fluorotaxol (II). The IC50 of II against L1210 leukemia was 0.0038 μg/mL. Capsule and tablet formulations of I are given.


IT 158810-72-1P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
 (preparation and reaction of, in preparation of antineoplastic agents)

RN 158810-72-1 CAPLUS

CN Benzenepropanoic acid, β-[[[(1,1-dimethylethoxy)carbonyl]amino]-α-hydroxy-, (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-12b-(acetyloxy)-12-(benzyloxy)-4-[[[(2,2-dichloroethoxy)carbonyl]oxy]-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-6,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester, (αR,βS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



=>